×

Indications

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal Read More

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, nonvertebral, and hip fractures.

Prolia® is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia® is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Prolia® also reduced the incidence of vertebral fractures.

Prolia® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. Close

Prolia® is the only FDA-approved therapy for cancer treatment–induced bone loss (CTIBL) due to hormone ablation therapy (CTIBL-HALT).1

Prolia®: The only approved therapy for prostate cancer treatment–induced bone loss due to ADT

“We investigated the effects of denosumab, a fully human* monoclonal antibody against [RANK Ligand], on bone mineral density and fractures in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer.”

—Smith MR, et al2

*Correlation with safety and efficacy is unknown.

Indication:
Prolia® is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients, Prolia® also reduced the incidence of vertebral fractures.

Study design1,2

Randomized, multinational, double-blind, phase 3 study assessing the effects of Prolia® vs placebo on BMD and new vertebral fractures

Men were stratified according to age ≥ 70 years or < 70 years. Men less than 70 years of age had either a BMD T-score at the lumbar spine, total hip, or femoral neck between -1.0 and -4.0, or a history of an osteoporotic fracture.

  • Patients were instructed to take ≥ 1000 mg of calcium and ≥ 400 IU of vitamin D supplementation daily.2

Study endpoints1,2

Primary endpoint:
  • Percent change in:
    • Lumbar spine BMD from baseline to 24 months
Select secondary endpoints:
  • Incidence of:
    • Newly diagnosed vertebral fracture through 36 months
  • Percent change in:
    • Lumbar spine BMD from baseline to 36 months
    • Total hip BMD from baseline to 36 months
    • Femoral neck BMD from baseline to 36 months